| KREJČÍ, Marta, Jiří MAYER, Michael DOUBEK, Yvona BRYCHTOVÁ, Z POSPÍŠIL, Zdeněk RÁČIL, Dana DVOŘÁKOVÁ, Martina LENGEROVÁ, Ondřej HORKÝ, Zdeněk KOŘÍSTEK, T DOLEŽAL a Jiří VORLÍČEK. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplantation. London: Nature Publishing Group, 2006, roč. 38, č. 7, s. 483-491. ISSN 0268-3369. |
Další formáty:
BibTeX
LaTeX
RIS
@article{838464,
author = {Krejčí, Marta and Mayer, Jiří and Doubek, Michael and Brychtová, Yvona and Pospíšil, Z and Ráčil, Zdeněk and Dvořáková, Dana and Lengerová, Martina and Horký, Ondřej and Kořístek, Zdeněk and Doležal, T and Vorlíček, Jiří},
article_location = {London},
article_number = {7},
keywords = {chronic myeloid leukemia; allogeneic stem cell transplantation; imatinib},
issn = {0268-3369},
journal = {Bone Marrow Transplantation},
title = {Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia},
volume = {38},
year = {2006}
}
TY - JOUR
ID - 838464
AU - Krejčí, Marta - Mayer, Jiří - Doubek, Michael - Brychtová, Yvona - Pospíšil, Z - Ráčil, Zdeněk - Dvořáková, Dana - Lengerová, Martina - Horký, Ondřej - Kořístek, Zdeněk - Doležal, T - Vorlíček, Jiří
PY - 2006
TI - Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia
JF - Bone Marrow Transplantation
VL - 38
IS - 7
SP - 483-491
EP - 483-491
PB - Nature Publishing Group
SN - 02683369
KW - chronic myeloid leukemia
KW - allogeneic stem cell transplantation
KW - imatinib
N2 - A reduced-intensity conditioning allogeneic stem cell transplantation was given to 19 patients (aged 15 - 59 years) in the first chronic phase and one patient in the accelerated phase with chronic myeloid leukemia (CML) after a regimen consisting of fludarabine (Flu), busulfan (Bu) and ATG Fresenius. The median follow-up was 27 months. The incidence of acute and chronic graft-versus-host disease (GvHD) was 55 and 75%, respectively. Two patients (10%) died from GvHD. Fourteen (70%) patients achieved molecular remission. Additional post-transplant intervention (donor lymphocyte infusion, imatinib) was necessary, however, in 10 patients (50% of the patients; non-achievement of stable molecular remission or later relapses). The total direct cost of the transplantation treatment for all of the patients came to 1 572 880 euro. If the patients had been treated with imatinib and followed-up with the same time period as they were following a transplantation, the direct cost of the imatinib treatment would have been 2 005 117 euro. The transplantation treatment appears to be less expensive after approximately 2 years of follow-up. Flu+Bu+ATG is a low-toxicity regimen for patients with CML. However, a close follow-up is necessary and about 50% of the patients require further therapeutic intervention.
ER -
KREJČÍ, Marta, Jiří MAYER, Michael DOUBEK, Yvona BRYCHTOVÁ, Z POSPÍŠIL, Zdeněk RÁČIL, Dana DVOŘÁKOVÁ, Martina LENGEROVÁ, Ondřej HORKÝ, Zdeněk KOŘÍSTEK, T DOLEŽAL a Jiří VORLÍČEK. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. \textit{Bone Marrow Transplantation}. London: Nature Publishing Group, 2006, roč.~38, č.~7, s.~483-491. ISSN~0268-3369.
|
